Next Level Private LLC Increases Position in Pfizer Inc. $PFE

Next Level Private LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 40.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,167 shares of the biopharmaceutical company’s stock after acquiring an additional 24,966 shares during the period. Next Level Private LLC’s holdings in Pfizer were worth $2,448,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. North Star Investment Management Corp. grew its stake in Pfizer by 12.2% in the first quarter. North Star Investment Management Corp. now owns 181,035 shares of the biopharmaceutical company’s stock valued at $5,083,000 after purchasing an additional 19,625 shares during the last quarter. 3Chopt Investment Partners LLC raised its holdings in Pfizer by 19.5% in the first quarter. 3Chopt Investment Partners LLC now owns 10,467 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 1,706 shares in the last quarter. Three Magnolias Financial Advisors LLC lifted its position in shares of Pfizer by 4.5% during the first quarter. Three Magnolias Financial Advisors LLC now owns 16,416 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 707 shares during the last quarter. Continuum Advisory LLC boosted its holdings in shares of Pfizer by 14.0% in the 1st quarter. Continuum Advisory LLC now owns 32,250 shares of the biopharmaceutical company’s stock valued at $906,000 after buying an additional 3,964 shares in the last quarter. Finally, Asset Allocation Strategies LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $233,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $24.27 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s fifty day moving average price is $25.94 and its 200-day moving average price is $26.29. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The firm has a market capitalization of $138.35 billion, a PE ratio of 18.53 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s payout ratio is 131.30%.

Analysts Set New Price Targets

Several research analysts recently commented on PFE shares. HSBC boosted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Tuesday, June 23rd. Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Finally, Guggenheim raised their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.82.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer, a regulatory win that could support use of the drug and modestly improve Pfizer’s oncology revenue outlook. FDA expands Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal for income-focused investors and signaling continued confidence in cash generation. Pfizer Declares Third-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer Ventures participated in a $62 million Series B for Oblenio Bio, highlighting the company’s broader innovation strategy, though the investment is not likely to have an immediate material impact on PFE shares. Oblenio Bio Closes $62 Million Series B…
• Neutral Sentiment: Pfizer halted a tafamidis bioequivalence study, which appears to be a study update rather than a major commercial setback, so the market reaction is likely limited unless further details emerge. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent investor concern remains tied to Pfizer’s mixed oncology pipeline news, especially the failed Phase 3 sigvotatug vedotin lung cancer study, which has pressured sentiment around the company’s long-term growth narrative. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.